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012.08.00Abstract Aim of the work: To assess the high sensitivity C-reactive protein (hs-CRP level) in sys-
temic lupus erythematosus (SLE) patients without cardiac involvement and ﬁnd its relation with
clinical and laboratory ﬁndings, disease activity, damage index and intima-media thickness (IMT).
Patients and methods: Forty-ﬁve female SLE patients were recruited in the present study without
any cardiac involvement. History taking, examination and laboratory investigations were per-
formed for patients. Disease activity was evaluated by the Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) and damage by the Systemic Lupus International Collaborating Clinics
(SLICC) index. Thirty age matched female healthy subjects were considered as a control group.
hs-CRP was measured quantitatively by microplate immunoenzymometric assay and the IMT mea-
sured by ultrasonography.
Results: The hs-CRP in the patients was signiﬁcantly higher (4.84 ± 3.91 mg/l) compared to the
control (1.74 ± 0.61 mg/l) (p< 0.001). The IMT in the patients was signiﬁcantly increased
(0.72 ± 0.37 mm) compared to the control (0.54 ± 0.15 mm) (p 0.004). There was no difference
in the level of hs-CRP according to the presence or absence of clinical manifestations. However,
it was signiﬁcantly higher in those with positive DNA (5.71 ± 4.36 mg/L) compared to those with1313069.
.com (I.I. El-Gazzar).
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148 T.A. Gheita et al.negative results (3.12 ± 1.97 mg/L) (p 0.009). There was a signiﬁcant correlation of the hs-CRP
level with the IMT (r 0.49, p 0.001) and SLEDAI (r 0.67, p< 0.001).
Conclusions: These ﬁndings suggest that SLE patients without traditional major cardiovascular
risk factors may have increased risk of future cardiac events. Measuring hs-CRP may be useful as a
marker of disease activity, increased IMT and subclinical atherosclerosis in SLE especially those
with positive ds-DNA.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Systemic lupus erythematosus (SLE) is a chronic inﬂammatory
multisystem disease characterized by a wide spectrum of clini-
cal manifestations accompanied by abnormalities of the im-
mune system. Although advances in therapeutic approaches
have taken place, SLE still has a profound impact on the qual-
ity of life [1]. It has been noted that increased CRP levels are
major predictors of cardiovascular diseases (CVD) in appar-
ently healthy subjects [2]. Concentrations of erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP) as
markers of inﬂammation were signiﬁcantly higher in SLE [3].
Coronary artery disease (CAD) is 5–8 times more often in
SLE patients compared to the general population and early
development of atherosclerosis is related to risk factors associ-
ated with the disease and its therapy [4].
C-reactive protein (CRP) is a plasma protein that is consid-
ered an acute phase reactant which serves clinically as a marker
of inﬂammation and tissue destruction [5]. It is produced by the
liver [6] and adipocytes [7] and then reaches the sites of inﬂam-
mation [8]. It shows no diurnal variation, however, liver failure
impairs its production [6]. Although measurement of CRP is
extensively used to monitor ongoing disease activity and
response to therapy, few clinicians are aware of its biological
signiﬁcance and many of its functions still remain unsolved [9].
The increased CRP levels in active SLE and in other sys-
temic inﬂammatory conditions suggest that it may be of path-
ogenic value as regards immunoregulation and autoimmunity
[10–12]. The suggested functions of CRP include mainly its
interaction with the immune system and inﬂammatory path-
ways. Its level rises dramatically during inﬂammation and falls
during periods of remission [6,7]. Its role as a marker for ath-
erosclerosis is highlighted and higher levels in SLE have been
associated with cerebrovascular diseases [13]. Moreover, its
dysregulation may be considered a feature of SLE and elevated
levels have been associated with increased cardiovascular risk
[14]. Though CRP is higher in active SLE, it does not essen-
tially have to correlate with disease activity. Raised CRP was
reported to be associated with anti ds-DNA antibodies, uri-
nary cellular casts, serositis and infection [15].
The development of high sensitivity C-reactive protein (hs-
CRP), with several folds improvement in sensitivity, allows it
to detect low levels of chronic inﬂammation which has been
associated with cardiovascular morbidity. Low levels of
chronic inﬂammation have been identiﬁed as an important
component in the development and progression of atheroscle-
rosis and hs-CRP constitutes an independent risk factor for
cardiovascular events [16]. Measurement of hs-CRP has been
used in the assessment of disease activity in numerous rheu-
matic conditions including SLE. However, the utility of itsmeasurement in lupus patients is uncertain [17]. While, the role
of CRP in SLE as an inﬂammatory marker is still controver-
sial, the more sensitive method measuring hs-CRP has been
used to detect micro-inﬂammation. The role of hs-CRP in lu-
pus ﬂare has not been documented well [18].
The aim of the present study was to assess the hs-CRP level
in SLE patients without cardiac involvement and ﬁnd its rela-
tion to clinical and laboratory features, disease activity and
damage indices. Correlation with intima media thickness
(IMT) was also considered a point of interest.2. Patients and methods
Forty-ﬁve female SLE patients were included in the present
study fulﬁlling the updated American College of Rheumatol-
ogy (ACR) revised criteria for the classiﬁcation of SLE [19].
All patients were recruited from the Rheumatology and Inter-
nal medicine departments and out patient clinics of Cairo Uni-
versity Hospitals. Patients were not known to have cardiac
involvement and those with history of diabetes mellitus, hyper-
tension, hyperlipidemia, cardiac and coronary artery disease or
recent infection with in the preceding month were excluded.
History taking, examination and laboratory investigations
were performed for patients. The antinuclear antibodies
(ANA), anti ds-DNA, lipid proﬁle, C3 and C4 were also as-
sessed. Disease activity was evaluated using the Systemic Lu-
pus Erythematosus Disease Activity Index (SLEDAI) [20]
and organ damage assessed by the Systemic Lupus Interna-
tional Collaborating Clinics/ACR (SLICC/ACR) index [21].
Thirty age matched female healthy subjects were considered
as a control group. The patients’ written consent was obtained
according to the declaration of Helsinki and the study has been
approved by local ethics committee prior to their inclusion in
the study.
2.1. Hs-CRP measurement
HS-CRP was measured quantitatively by microplate immuno-
enzymometric assay (Immulite 2000; Diagnostic Products, Los
Angeles, CA, USA) and interpreted in the ranges of <3 mg/l
(normal and low risk) and =3 mg/l (high risk).
2.2. Measurement of intima-media thickness (IMT)
In order to estimate early-stage atherosclerosis ultrasono-
graphic scanning of the carotid artery was performed using
an echographic system (ATL HDI 5000, USA) with an electric
linear transducer (mid-frequency 7.5 MHz) and a detection
limit of 0.1 mm. Scanning of the extracranial common carotid
Table 2 Laboratory investigations of the SLE patients.
Laboratory investigation SLE patients (45)
Hs-CRP (mg/l) 4.84 ± 3.91
ESR 1st hour (mmHg) 62.87 ± 22.04
Hemoglobin (g%) 9.94 ± 2.19
WBCs (·103/mm3) 8.23 ± 4.06
Platelets (·103/mm3) 282.16 ± 127.46
AST (U/L) 36.3 ± 15.91
ALT (U/L) 33.22 ± 16.15
ALP (IU/L) 104.87 ± 51.84
Albumin (g/dl) 3.4 ± 0.7
Creatinine (mg/dl) 0.55 ± 0.15
Urine protein (g/24 h) 0.37 ± 0.43
Serum uric acid (mg/dl) 5.11 ± 3.11
Triglycerides (mg/dl) 155.29 ± 69.04
Cholesterol (mg/dl) 184.2 ± 47.58
HDL (mg/dl) 47.67 ± 13.12
LDL (mg/dl) 152.11 ± 30.91
FBS (mg/dl) 96.38 ± 10.7
C3 (mg/dl) 0.8 ± 0.46
C4 (mg/dl) 0.15 ± 0.1
ANA positivity 43 (95.56)
Anti-ds-DNA positivity 30 (66.67)
Hs-CRP: high sensitivity C-reactive protein, ESR: Erythrocyte
sedimentation rate, AST: Aspartate transaminase, ALT: Alanine
transaminase, ALP: Alkaline phosphatase, HDL: High density
lipoprotein, LDL: Low density lipoprotein, FBS: fasting blood
sugar, C: complement, ANA: Antinuclear antibodies, Anti-ds-
DNA: anti-double stranded DNA. Results are presented as
mean ± SD or No (%).
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performed bilaterally from two longitudinal (anterolateral and
posterolateral) and cross-sectional scans. Characteristic pat-
terns showed two parallel echogenic lines separated by a hyp-
oechogenic space. The IMT was deﬁned as the distance from
the leading edge of the ﬁrst echogenic line to the leading edge
of the second line. The ﬁrst line represented luminal-intimal
transition and the second one medial-adventitial transition.
The site of the greatest thickness including a plaque lesion
was sought along the arterial walls. Three determinations of
IMT were conducted at the thickest and two adjacent points
(1 cm upstream and 1 cm downstream from the thickest point)
and were averaged (mean IMT).
Analysis of data was performed with a statistical package
for the social sciences (SPSS) version 15. Data were presented
as mean ± standard deviation. Mann–whitney test was used
for analysis of two non parametric quantitative data. Correla-
tion was performed by Spearman correlation coefﬁcient. The p
value was considered signiﬁcant if <0.05.
3. Results
Forty-ﬁve female SLE patients had a mean age of
26.13 ± 7.21 years and a disease duration of 3.68 ± 2.5 years.
Thirty age matched subjects (27.37 ± 2.48 years) formed the
control group. Secondary amenorrhea was present in 2 patients
and irregular menses in another 2, while all other patients had
regular menstrual cycles. None of the patients or control was
smoking. All patients were receiving oral corticosteroids and
additionally, 17 patients were receiving hydroxychloroquine,
12 azathioprine, 5 cyclophosphamide, 1 methotrexate and 3
oral anticoagulants (warfarin). The patients had no cardiac
involvement by history or clinical examination and the electro-
cardiograms were normal. Patients with pulmonary manifesta-
tions with suspicion of cardiac involvement were performed an
echocardiography which was essentially normal. The pulmon-
ary manifestations were in the form of a mild pleural rub. Five
patients had secondary antiphospholipid syndrome with a his-Table 1 Demographic and Clinical features of the SLE
patients.
Feature SLE patients (45)
Age (years) 26.13 ± 7.21
Disease duration (years) 3.68 ± 2.5
BMI 26.01 ± 2.32
SBP (mmHg) 127.78 ± 15.36
DBP (mmHg) 79.11 ± 12.4
Prednisolone (mg/day) 22.33 ± 12.18
Mucocutaneous 29 (64.44)
Arthritis 18 (40)
Nephritis 25 (55.56)
Hematological 33 (73.33)
Neuropsychiatric 27 (60)
Gastrointestinal 5 (11.11)
Pulmonary 9 (20)
SLEDAI 7.31 ± 4.15
SLICC 2.11 ± 1.51
BMI: body mass index, SBP: Systolic blood pressure, DBP: Dia-
stolic blood pressure, SLEDAI: Systemic lupus erythematosus
disease activity index, SLICC: Systemic Lupus International Col-
laborating Clinics. Results are presented as mean ± SD or No (%).tory of DVT in two. Clinical and laboratory features of the SLE
patients are seen in Tables 1 and 2.
The hs-CRP in the SLE patients was signiﬁcantly higher
(4.84 ± 3.91 mg/l) compared to the control (1.74 ± 0.61 mg/l)
(p< 0.001) (Fig. 1). Twenty had a low risk level of hs-CRPFigure 1 The hs-CRP level in the SLE patients and control.
Figure 2 The IMT in the SLE patients and control.
Figure 3 Correlation of the hs-CRP and IMT in the SLE
patients.
Figure 4 Correlation of the hs-CRP with SLEDAI in the SLE
patients.
Figure 5 Correlation of the IMT with SLEDAI in the SLE
patients.
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cantly increased (0.72 ± 0.37 mm) compared to the control
(0.54 ± 0.15 mm) (p 0.004) (Fig. 2). The IMT was signiﬁcantly
increased in the SLE patients with high risk CRP level
(0.83 ± 0.42 mm) compared to those at lower levels
(0.59 ± 0.24 mm) (p 0.02). Two of the high risk level hs-CRP
patients had plaque lesions. There was no difference in the
level of hs-CRP according to the presence or absence of clinical
manifestations. However, it was signiﬁcantly higher in those
with positive DNA (5.71 ± 4.36 mg/L) compared to those
with negative results (3.12 ± 1.97 mg/L) (p 0.009).
There was a signiﬁcant correlation between the hs-CRP le-
vel and IMT (r 0.49, p 0.001) (Fig. 3). The hs-CRP signiﬁcantly
correlated with the ESR (r 0.63, p< 0.001) and SLEDAI
(r 0.67, p< 0.001) and negatively with the Hb content
(r 0.56, p< 0.001). The IMT correlated with the serum uric
acid (r 0.37, p 0.01), HDL (r 0.37, p 0.01) and SLEDAI (r 0.38,
p 0.01). There was no signiﬁcant correlation between thehs-CRP and the dose of corticosteroids (r 0.06, p 0.68). Figs. 4
and 5 illustrate the correlation of the hs-CRP and IMT with
SLEDAI in the SLE patients.
4. Discussion
Morbidity and mortality secondary to premature CVD in SLE
remain signiﬁcant issues and the pathogenesis has not been
fully explored [22]. Yet, it has been reported that hs-CRP rep-
resents a risk factor for CVD in lupus patients [23] and it has
been hypothesized that CRP itself could be the link between
disease activity and CVD [24]. In the present work, the hs-
CRP was signiﬁcantly higher in the patients than in control.
In accordance with these results is the study of de Leeuw
et al., [25] who found CRP to be signiﬁcantly higher even in
inactive SLE patients. Another study found the serum level
of hs-CRP to be signiﬁcantly higher in SLE [18]. Although car-
diovascular disease has been acknowledged as a primary cause
of morbidity and mortality in SLE, cardiac manifestations
(when present) are often mild and subclinical [26]. When very
sensitive methods of investigation are used, the prevalence
of cardiac involvement was found to be >50% [27] and
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ography and other non-invasive tests [28].
Measurement of hs-CRP, has been used in the assessment
of disease activity in numerous rheumatic conditions including
SLE. However, the utility of hs-CRP measurement in patients
with lupus is uncertain [17]. The hs-CRP may be useful to
monitor the course of the disease and predict its intermediate
outcome, but longitudinal studies with serial measurements
are necessary to deﬁne its clinical value [29]. In the present
study, the hs-CRP signiﬁcantly correlated with the ESR and
SLEDAI but not with the SLICC damage index. Similarly,
in another study hs-CRP was associated with disease activity
but not with overall damage accrual; however, it correlated
with speciﬁc domains of the damage index. [29]. In agreement
with these results are the ﬁndings that SLE exacerbations were
accompanied by CRP levels >10 mg/L in about 60% of pa-
tients [30,31]. In disagreement was the study that found that
hs-CRP was not associated with SLEDAI which makes its va-
lue as a marker of disease activity questionable, yet it is useful
in the assessment of cardiovascular risk [17,18]. Furthermore,
in other studies a high proportion of uninfected lupus patients
had clinically signiﬁcant CRP elevation which did not correlate
with disease activity [17,32]. Moreover, some patients with
inactive lupus and without infection were found to have
CRP levels >10 mg/L [33].
It was found that in SLE patients the ESR and CRP values
modestly correlated with each other and weakly with disease
activity suggesting that another look at their roles as markers
of inﬂammation in routine care may be in order [34]. In the
present study, the CRP level was not as high as expected. It
has been reported that CRP remains low despite high disease
activity in SLE as these patients have circulating autoantibod-
ies against monomeric CRP (mCRP) which may form a possi-
ble explanation [35,36] and the level of these antibodies
correlated with disease activity [36]. In the present study, hs-
CRP was found to be higher in those with positive anti-
ds-DNA. Anti-CRP positively correlated with SLEDAI scores
and anti-DNA antibody levels [36]. It has been found that SLE
patients with higher CRP and anti-CRP antibodies showed
increased frequencies of anti-dsDNA antibodies compared to
those without [37].
In the current study there was no signiﬁcant difference of
the hs-CRP level according to the presence and absence of clin-
ical manifestations and no signiﬁcant correlation was present
with most of the studied parameters except negatively with
the Hb content. The study of Panaﬁdina et al., [4] found a sig-
niﬁcant correlation of hs-CRP with hematological distur-
bances including anemia [4]. In another study, hs-CRP did
not correlate with any of the laboratory parameters, except
negatively for C3 and C4 [18]. The present SLE patients did
not have any cardiac involvement and there was no difference
in the hs-CRP level according to the presence or absence of
clinical manifestations. However, in a previous study, CRP
was found to be signiﬁcantly elevated in a subset of SLE pa-
tients with pericardial effusion [38].
In the present study the serum level of hs-CRP signiﬁcantly
correlated with the IMT in the SLE patients. A slight increase
in hs-CRP is thought to reﬂect the presence of subclinical inﬂam-
mation in the vascular wall, connected with atherosclerotic pro-
cess and is found to moderately correlate with the IMT [4]. The
hs-CRP correlated with the cardiovascular domain of the
SLICC damage index [29] and was associated with aortic valvecalciﬁcation in SLE [39]. Inﬂammation is pivotal in atheroscle-
rosis and minor CRP response reﬂects low-grade vascular
inﬂammation. The connection of CRP with cardiovascular dis-
ease in SLE has been suggested [40].The circulating concentra-
tion of liver-derived CRP rises rapidly in response to
infections and tissue injury, and its measurement is widely em-
ployed as a marker of ongoing inﬂammation. With sensitive
methods, the detection of small elevations of hs-CRP is even
more valuable as a prognostic marker in cardiovascular diseases
[9].
In the present work, all patients were receiving oral cortico-
steroids. There was no signiﬁcant correlation between the dose
of corticosteroids and hs-CRP. The role of corticosteroids in
lupus-associated atherogenesis is rather controversial, as these
agents may themselves be directly atherogenic, but they may
also indirectly prevent premature atherosclerosis by control-
ling disease activity [41,42].
In conclusion, these ﬁndings suggest that SLE patients
without traditional major cardiovascular risk factors may have
increased risk of future cardiac events. Measuring hs-CRP may
be useful as a marker of disease activity, increased IMT and
subclinical atherosclerosis in SLE especially those with positive
ds-DNA. It is recommended that a larger scale longitudinal
study is conducted to follow up changes and study its relation
to the disease outcome.Conﬂict of interest
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